ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen in the NEWS
Immunogen (IMGN) - a developer of  antibody-drug conjugates (ADCs) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
From ImmunoGen
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “Building on the momentum generated in the first half of 2023, we delivered a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.